Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 98,052 | 108,309 | 100,496 | 103,348 | 90,703 |
| Cost of Goods | 10,987 | 9,914 | 12,257 | 5,319 | 8,631 |
| Gross Profit | 87,065 | 98,395 | 88,239 | 98,029 | 82,072 |
| Operating Expenses | 233,149 | 247,266 | 242,601 | 243,976 | 307,769 |
| Operating Income | -145,097 | -147,957 | -154,105 | -145,628 | -225,066 |
| Interest Expense | 17,665 | 15,375 | 15,636 | 15,874 | 14,505 |
| Other Income | 3,763 | 4,236 | 6,264 | 8,218 | 752 |
| Pre-tax Income | -158,999 | -159,096 | -163,477 | -153,284 | -238,819 |
| Income Tax | 650 | 732 | 495 | -1,451 | 6,287 |
| Net Income Continuous | -159,649 | -159,828 | -163,972 | -151,833 | -245,106 |
| Net Income | $-159,649 | $-159,828 | $-163,972 | $-151,833 | $-245,106 |
| EPS Basic Total Ops | -2.23 | -2.25 | -2.33 | -2.17 | -3.50 |
| EPS Basic Continuous Ops | -2.23 | -2.25 | -2.33 | -2.17 | -3.50 |
| EPS Diluted Total Ops | -2.23 | -2.25 | -2.33 | -2.17 | -3.50 |
| EPS Diluted Continuous Ops | -2.23 | -2.25 | -2.33 | -2.17 | -3.50 |
| EBITDA(a) | $-140,587 | $-145,815 | $-151,863 | $-142,321 | $-219,403 |